Adage Capital Partners Gp, L.L.C. Ambrx Biopharma Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.41 - $4.54 $410,000 - $4.54 Million	-1,000,000 Reduced 49.33%	1,027,291 $2.33 Million
Q1 2022 May 16, 2022	BUY	$4.07 - $9.0 $421,615 - $932,319	103,591 Added 5.38%	2,027,291 $8.35 Million
Q4 2021 Feb 14, 2022	BUY	$8.11 - $13.91 $781,868 - $1.34 Million	96,408 Added 5.28%	1,923,700 $17.4 Million
Q2 2021 Aug 16, 2021	BUY	$15.95 - $19.6 $29.1 Million - $35.8 Million	1,827,292 New	1,827,292 $35.8 Million

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.